Your browser doesn't support javascript.
loading
The Clinical Response of Upadacitinib and Risankizumab Is Associated With Reduced Inflammatory Bowel Disease Anti-TNF-α Inadequate Response Mechanisms.
Wang, Jing; Macoritto, Michael; Guay, Heath; Davis, Justin W; Levesque, Marc C; Cao, Xiaohong.
Afiliação
  • Wang J; Genomic Research Center, AbbVie Inc, Cambridge, MA, 02139, USA.
  • Macoritto M; Genomic Research Center, AbbVie Inc, Cambridge, MA, 02139, USA.
  • Guay H; AbbVie Bioresearch Center, Worcester, MA, 01605, USA.
  • Davis JW; Genomic Research Center, AbbVie Inc, North Chicago, IL, 60064, USA.
  • Levesque MC; AbbVie Cambridge Research Center, Cambridge, MA, 02139, USA.
  • Cao X; Genomic Research Center, AbbVie Inc, Cambridge, MA, 02139, USA.
Inflamm Bowel Dis ; 29(5): 771-782, 2023 05 02.
Article em En | MEDLINE | ID: mdl-36515243
We identified molecular and cellular mechanisms associated with and potentially mediating the response of upadacitinib and risankizumab for IBD patients that inadequately responded to anti-TNF-α treatment.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças Inflamatórias Intestinais / Inibidores do Fator de Necrose Tumoral Tipo de estudo: Clinical_trials / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças Inflamatórias Intestinais / Inibidores do Fator de Necrose Tumoral Tipo de estudo: Clinical_trials / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article